In the Hot off the Press section of Molecular BioSystems members of the Editorial Board and their research groups highlight recent literature for the benefit of the community. This month the highlighted topics include MALDI-TOF analysis of siRNA degredation published in this issue of Molecular BioSystems, one of our most regular contributers to Hot off the Press Ljiljana Fruk and an item published recently in one of the RSC’s journals.
The group at the MRC are well known for studies into the delivery of therapeutic nucleic acid analogues into cellular environments. As such, part of this study focussed on the study of the breakdown of cell penetrating peptides and delivery reagents, such as cholesterol, conjugated to the siRNA. This data was also compared to data acquired by polyacrylamide gel electrophoresis to demonstrate that the breakdown was occurring in the siRNA and not the peptide or cholesterol. The mass spectral data indicated cleavage at a particular point in the sequence and convincingly demonstrated that the method of activity of the enzyme was based on a RNAse A type cleavage mechanism, i.e. degradation occurred internally within the siRNA as opposed to degradation from one of the terminals as in an exonuclease activity. The data obtained from the MALDI-TOF indicates that the cleavage occurs after pyrimidine nucleotide residues. The authors also say that the RNAse A like activity is unlikely to recognise and cleave double stranded RNA, and it is therefore probable that the cleavage only takes place when the siRNA duplex is breathing and a region of single stranded RNA is produced. This again fits in with the observation that the cleavage takes place at a pyrimidine base site and in particular the UpA region especially if at one end of the duplex. If the UpA sequence is near the centre it was found that the cleavage rate was much slower and did not appear to be any more vulnerable than other pyrimidines in the duplex. This is important as most siRNA duplexes have been designed to be either A or U rich at one end and this now allows appropriate modification of the pyrmidine to improve stability. This is a highly significant result as it is the first time that this has been demonstrated experimentally and it also indicates how siRNA can be made less susceptible to cleavage by careful positioning of modified ribonucleotides. If for instance a 2′-O-methyl group is used then at the cleavage site then the siRNA is rendered stable to degradation in the serum samples. The information gained from this study allows the careful positioning of the modified base at the enzyme cleavage site as opposed to a blanket coverage of modification of pyrimidine bases and will have significant impact on the ability of siRNA to exist in complex biological systems. This is an important advance in the understanding of siRNA stability and the mechanism of degradation in serum and will have significant impact on the future use of siRNA as a potential therapeutic agent.
John J. Turner, Simon W. Jones, Sterghios A. Moschos, Mark A. Lindsay and Michael J. Gait Molecular BioSystems, 2007, 3(1), 43–50.
Reviewed by: Duncan Graham, University of Strathclyde.
More details on: http://www.chemie.uni-dortmund.de/groups/niemeyer/ljiljana/indexljiljana.html
![]() | ||
Scheme 1 Reprinted with permission from F. P. Seebeck, A. Guainazzi, C. Amoreira, K. K. Baldrige, D. Hilvert, Angew. Chem., Int. Ed. 2006, 45, 6824–6826. |
Now the same group has shown that this engineered enzyme catalyses also retro-aldol reaction of α-substituted β-phenylserines with high stereoactivity. This type of reaction involving quaternary α-amino acids is not observed in natural aldolase, but it has a huge potential in chemical synthesis of amino acids. To start with, two β-hydroxyl amino acids with additional α-substituents were synthesized (2a, 2b). In the presence of alrY265A this amino acids initially react with enzyme bound PLP (3) which is then followed by Cα–Cβ bond cleavage of the adduct. In subsequent steps the product intermediate is protonated and hydrolyzed (by Lys39 or water) to give glycine (or alanine) and regenerated catalyst. The kinetic parameters obtained for this reaction showed that substrate is consumed with higher catalytic efficiency than in case of (2R, 3S)-β-phenylserine. The data also indicated that there is poor steroechemical control at β, but very high at α carbon. Additionally, computational (docking and ab initio) methods were used to investigate substrate binding to the active site of the enzyme giving insight into possible additional optimization of the mutant. This exciting contribution to the field of biocatalysis may soon prove to be a very important route to the enantioselective synthesis of novel amino acids.
F. P. Seebeck, A. Guainazzi, C. Amoreira, K. K. Baldrige, D. Hilvert, Angew. Chem., Int. Ed. 2006, 45, 6824–6826.
Reviewed by: Ljiljana Fruk, University of DortmundMartin Yarmush and a team at Massachusetts General Hospital, Boston, US, have developed a microfluidic device that allows them to study gene expression, the production of proteins from genes, in living cells.
Previously, scientists looking at gene expression would have to make destructive measurements, said Yarmush. The cell would be broken up for analysis, giving a snapshot of its response to a stimulus, he explained. Long term responses had to be assembled from separate cell populations.
Using the microfluidic system, the team was able to monitor gene expression continually, a so-called dynamic study. By altering the genes to express fluorescent proteins and exposing the cells to different conditions, the team could measure the effects on gene expression as a change in fluorescence.
The group developed its array to help study liver biology and disease. Yarmush explained that ‘the technology might help us advance from building static models of disease states to dynamic models of disease processes.’ The method also opens ‘additional possibilities’ for screening potential drugs, optimising the timing and doses of combination therapies, and studying the mechanisms underlying cell damage and recovery, he said.
As well as the benefits from being able to study the living cell, the microfluidic array allows fast, high-throughput analysis which is cheaper than existing options. Yarmush added, ‘the platform has already dramatically increased experimental throughput 100-fold, and there is tremendous potential for further scaling.’
![]() | ||
Fig. 1 The array can monitor the effects of drugs and disease on living cells. Reproduced from Lab Chip, 2006, DOI: 10.1039/b612516f by permission of The Royal Society of Chemistry. |
KR King, S Wang, D Irimia, A Javaraman, M Toner and ML Yarmush, Lab Chip, 2006, DOI: 10.1039/b612516f.
Reviewed by: Laura Howes, Royal Society of Chemistry, Cambridge.This journal is © The Royal Society of Chemistry 2007 |